GEN-MKT-18-7897-A
Mar 2, 2018 | Blogs, Forensic | 0 comments
Drug overdose has become one of the leading causes of death of Americans under 50. If that’s not bad enough, let’s put this into perspective.
America makes up only 4% of the world population. In 2015, it recorded 52,400 drug-related deaths, which is about 27% of the world’s drug overdose fatalities. That ballooned to 64,000 deaths in 2016. The only other comparable outbreak that hit the US this rampant was the HIV epidemic in the late 1980s.
The culprit: fentanyl and other synthetic opioids. These powerful drugs boost the body’s feel-good hormone; dopamine; which results in an intense feeling of prolonged euphoria. With frequent use, the brain becomes conditioned and craves more drugs to sustain the same level of feeling.
It’s that reason; these drugs are very addictive and responsible year-on-year spikes in overdose-related deaths.
A Forensic FathomA more significant concern of this scientific puzzle is the emergence of synthetic opioids.
One of the most common fentanyl is between 50-100 times more potent than morphine. Then there are other analogs such as carfentanil, used as tranquilizers for large animals like elephants or obscure names like furanylfentanyl or ohmefentanyl or U-47700. These substances can be 10,000 times stronger and so powerful that as little as a few grains of salt could kill an adult human!
Whether it’s cooked up by manufacturers or kitchen labs in the US, these substances tend to be laced with chemicals that most drug screens aren’t designed to identify. Often the slightly altered chemical structures whether to increase potency or narrowly evade regulations, it could go under the radar of many drug screens.
The constant alteration has left many public health workers, police and even users baffled. Forget an accurate ingredient list when these substances are likely illegally obtained, making clear identification almost impossible.
As such, forensic investigators are challenged to unravel a mystery; not knowing what they’re up against.
The Power of SWATH® AcquisitionThus, fast, accurate laboratory testing is even more crucial to detect opioid intoxication today than before.
That’s precisely what SWATH Acquisition is for! Reduce the risk of missing critical compounds samples, through comprehensive data acquisition strategy that yield high detection sensitivity and drug specificity crucial to forensic investigators.
In this technical note, the use of SWATH Acquisition for the ultra-fast and accurate identification of novel synthetic opioids present in different seized drug samples was evaluated, and compared to typical GC-MS analysis.
Let SWATH Acquisition lead the way to reliable, comprehensive synthetic opioid characterization.
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network